Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sagimet Biosciences Inc.NASDAQ: SGMT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow grows to $0
Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 130K | — |
| FY2021 | 2021-12-31 | 0 | — |
Depreciation & Amortization vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 depreciation & amortization of $0 is the smallest of the 11 companies compared; the peer median is $473.56K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $284K | -92.5% | +29.3% | 4.9% | |
| LTM Mar 2026 | $223K | -4.7% | -1.1% | — | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +229.4% | — | — |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding SGMT) | $473.56K | -5.4% | -4.3% | 8.1% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.